← Russell 3000 cross-section

PACB PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$483m
Revenue TTM
$159m
Net income TTM
$-131m
Free cash flow
$-123m
Composite score
Sector rank
#2414

Valuation

P / E
EV / EBITDA
EV / sales
1.5
FCF yield
-25.54%
Earnings yield vs 10-yr
-31.92pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-82.5%
EBITDA margin
-75.5%
ROE
395.6%
ROIC
Revenue growth
2.0%

Insider activity, last 90 days

Net open-market
$-0.03m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Key highlights of the six months ended June 30, 2026 consolidated financial results include the following: • Revenue was comprised of $22.6 million in instrument revenue, $41.9 million in consumables revenue and $11.7 million in service and other revenue during the six months ended June 30, 2026. Revenue was comprised of $25.2 million in instrument revenue, $39.0 million in consumables revenue and $12.7 million in service and other revenue during the six months ended June 30, 2025. Lower Vega unit sales and a decrease in service and other revenue were partially offset by an increase in consumables revenue and higher Revio unit sales. …PACIFIC BIOSCIENCES OF CALIFORNIA, INC., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →